Medical Oncology

Inclusion Criteria

- Male or female subjects aged =/> 18 years
 - Subjects with advanced, histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, have no standard therapy available, or subjects actively refused any standard treatment and / or if, in the judgment of the investigator, experimental treatment is clinically and ethically acceptable.
 - For the expansion cohort: women with histologically or cytologically confirmed triple negative breast cancer (TNBC)
 - Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
 - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
 - Life expectancy of at least 12 weeks
 - Adequate bone marrow, liver, and renal functions

Exclusion Criteria

- Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study
 - Evidence of peripheral neuropathy of Grade > 2
 - History of cardiac disease:  congestive heart failure New York Heart Association (NYHA) class > II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted)
 - Prior treatment with more than 3 lines of cytostatic therapies for metastatic disease unless specifically agreed between investigator and sponsor. Subjects with a history of any prior Grade =/> 3 toxicity associated with taxane treatment will be excluded.
 - Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management
 - Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C
 - History of human immunodeficiency virus (HIV) infection.